https://www.biopharmawatch.com/news/OMDA/omada-health-q3-2026-results-conference-call BiopharmaWatch en 2026-10-13T13:05:00.000Z Omada Health to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-vatnak-vat-ho-cbo BiopharmaWatch en 2026-10-13T13:01:00.000Z Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering https://www.biopharmawatch.com/news/AUNA/auna-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-13T13:00:00.000Z Auna Announces Reporting Dates for Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-q3-2026-earnings-release BiopharmaWatch en 2026-10-13T13:00:00.000Z Acadia Healthcare Announces Date for Third Quarter 2026 Earnings Release https://www.biopharmawatch.com/news/EHTH/ehealth-launches-ai-content-genius-platform BiopharmaWatch en 2026-10-13T13:00:00.000Z eHealth Launches AI-Powered "Content Genius" Platform to Streamline Operations for the Medicare Annual Enrollment Period https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-fortune-best-workplaces-2026 BiopharmaWatch en 2026-10-13T12:45:00.000Z Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ovarian-cancer-conference-keynote BiopharmaWatch en 2026-10-13T12:40:00.000Z Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference https://www.biopharmawatch.com/news/MTVA/metavia-appoints-sarah-browne-cmo BiopharmaWatch en 2026-10-13T12:31:00.000Z MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer https://www.biopharmawatch.com/news/ACOG/alpha-cognition-patent-application-benzgalantamine BiopharmaWatch en 2026-10-13T12:30:00.000Z Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL® https://www.biopharmawatch.com/news/SSII/ss-innovations-fda-response-ss-mantra BiopharmaWatch en 2026-10-13T12:30:00.000Z SS Innovations Submits Response to FDA Request for Additional Information Regarding the Company’s 510(k) Submission for the SSi Mantra https://www.biopharmawatch.com/news/WVE/wave-life-sciences-chardan-healthcare-conference-2026 BiopharmaWatch en 2026-10-13T12:30:00.000Z Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/MDAI/spectral-ai-deepview-system-acep-2026 BiopharmaWatch en 2026-10-13T12:30:00.000Z Spectral AI’s DeepView™ System Showcased at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly https://www.biopharmawatch.com/news/ICCM/icecure-eusobi-2026-prosense-breast-cancer-cryoablation BiopharmaWatch en 2026-10-13T12:05:00.000Z IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026 https://www.biopharmawatch.com/news/SCNX/scienture-reports-preliminary-q3-2026-revenue-growth BiopharmaWatch en 2026-10-13T12:05:00.000Z SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth https://www.biopharmawatch.com/news/BFLY/vcom-butterfly-network-ultrasound-education-alliance BiopharmaWatch en 2026-10-13T12:02:00.000Z The Edward Via College of Osteopathic Medicine (VCOM) and Butterfly Network Announce Long-Term Alliance to Build New Model for Ultrasound Education https://www.biopharmawatch.com/news/A/agilent-acquire-proscia-digital-pathology BiopharmaWatch en 2026-10-13T12:00:00.000Z Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-present-positive-research-data-cheast-2026 BiopharmaWatch en 2026-10-13T12:00:00.000Z bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 https://www.biopharmawatch.com/news/COYA/coya-therapeutics-chardan-healthcare-conference-2023 BiopharmaWatch en 2026-10-13T12:00:00.000Z Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/ENGN/engene-host-kol-webinar-october-2026 BiopharmaWatch en 2026-10-13T12:00:00.000Z enGene to Host KOL Webinar on October 15, 2026 https://www.biopharmawatch.com/news/CRL/charles-river-magellan-stem-cells-collaboration BiopharmaWatch en 2026-10-13T12:00:00.000Z Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development https://www.biopharmawatch.com/news/RVTY/revvity-present-upcoming-investor-conferences-20261013 BiopharmaWatch en 2026-10-13T12:00:00.000Z Revvity to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/ATRC/atricure-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-13T12:00:00.000Z AtriCure to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LH/labcorp-thrive-global-launch-thrive-5-health-test BiopharmaWatch en 2026-10-13T12:00:00.000Z Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test https://www.biopharmawatch.com/news/WAT/waters-launches-ai-link-advancing-ai-enabled-lc-ms-workflows BiopharmaWatch en 2026-10-13T12:00:00.000Z Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release https://www.biopharmawatch.com/news/CGON/cg-oncology-appoints-isabel-kalofonos-cco BiopharmaWatch en 2026-10-13T12:00:00.000Z CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer https://www.biopharmawatch.com/news/STTK/shattuck-labs-poster-presentations-ueg-week-2026 BiopharmaWatch en 2026-10-13T12:00:00.000Z Shattuck Labs Announces Two Poster Presentations at UEG Week 2026 https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-restructuring-savings-plan BiopharmaWatch en 2026-10-13T12:00:00.000Z Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth https://www.biopharmawatch.com/news/IMMP/immutep-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-10-13T12:00:00.000Z Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/MBX/mbx-biosciences-participate-upcoming-november-investor-conferences BiopharmaWatch en 2026-10-13T12:00:00.000Z MBX Biosciences to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-chardan-healthcare-conference BiopharmaWatch en 2026-10-13T12:00:00.000Z Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/ATYR/atyr-pharma-atyr0101-fibrosis-therapy BiopharmaWatch en 2026-10-13T12:00:00.000Z aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-patent-tbs-2025 BiopharmaWatch en 2026-10-13T11:45:00.000Z TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 https://www.biopharmawatch.com/news/ZTS/zoetis-appoints-iris-knobloch-board-directors BiopharmaWatch en 2026-10-13T11:30:00.000Z Zoetis Appoints Iris Knobloch to its Board of Directors https://www.biopharmawatch.com/news/CGC/canopy-growth-smiths-falls-eu-gmp-certification BiopharmaWatch en 2026-10-13T11:30:00.000Z Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower https://www.biopharmawatch.com/news/NTRA/natera-transcode-phase-2a-trial-ttx-mc138-colorectal-cancer BiopharmaWatch en 2026-10-13T11:30:00.000Z Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-think-surgical-distribution-agreement BiopharmaWatch en 2026-10-13T11:30:00.000Z ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT https://www.biopharmawatch.com/news/KURA/caspian-kura-ko-7246-development-strategy-diabetes BiopharmaWatch en 2026-10-13T11:30:00.000Z Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-chardan-healthcare-conference BiopharmaWatch en 2026-10-13T11:30:00.000Z Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-cheast-2026-presentation BiopharmaWatch en 2026-10-13T11:30:00.000Z Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting https://www.biopharmawatch.com/news/RGEN/repligen-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-13T11:30:00.000Z Repligen to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BWAY/brainsway-reports-rise-in-coverage-for-deep-tms BiopharmaWatch en 2026-10-13T11:30:00.000Z BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives https://www.biopharmawatch.com/news/CRON/cronos-spinach-green-apple-products-return-fall BiopharmaWatch en 2026-10-13T11:30:00.000Z Fan-Favorite and Limited-Edition Spinach® Green Apple-Flavored Products are Returning for the Fall Season https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-appoints-jing-marantz-cmo BiopharmaWatch en 2026-10-13T11:30:00.000Z Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer https://www.biopharmawatch.com/news/MRK/paul-diaz-elected-merck-board BiopharmaWatch en 2026-10-13T11:02:00.000Z Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors https://www.biopharmawatch.com/news/PRLD/prelude-lilly-collaboration-evaluate-prt13722-breast-cancer BiopharmaWatch en 2026-10-13T11:01:49.000Z Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-beam-301-gsdi-trial-data-esgct BiopharmaWatch en 2026-10-13T11:00:41.000Z Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-successful-cgmp-batch-ph-762 BiopharmaWatch en 2026-10-13T11:00:40.000Z Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance https://www.biopharmawatch.com/news/NBP/visara-expands-ophthalmology-pipeline-nerve-growth-factor-therapy BiopharmaWatch en 2026-10-13T11:00:00.000Z Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis https://www.biopharmawatch.com/news/ENTX/entera-eb613-anabolic-effects-osteoporosis-asbmr-2026 BiopharmaWatch en 2026-10-13T11:00:00.000Z Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting https://www.biopharmawatch.com/news/IBIO/ibio-610-muscle-preservation-glp-1-therapy BiopharmaWatch en 2026-10-13T11:00:00.000Z iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy https://www.biopharmawatch.com/news/PFE/enodia-therapeutics-pfizer-collaboration-sec61 BiopharmaWatch en 2026-10-13T11:00:00.000Z Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules https://www.biopharmawatch.com/news/PFE/enodia-therapeutics-pfizer-sec61-inhibitors BiopharmaWatch en 2026-10-13T11:00:00.000Z Enodia Therapeutics gibt eine Forschungskooperation und eine Lizenzvereinbarung mit Pfizer zur Entwicklung von Sec61-gerichteten niedermolekularen Wirkstoffen bekannt https://www.biopharmawatch.com/news/ALKS/alkermes-sleep-europe-2026-presentation BiopharmaWatch en 2026-10-13T11:00:00.000Z Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-zelicapavir-idweek-2026 BiopharmaWatch en 2026-10-13T11:00:00.000Z Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 https://www.biopharmawatch.com/news/PFE/enodia-therapeutics-pfizer-research-collaboration BiopharmaWatch en 2026-10-13T11:00:00.000Z Samenvatting: Enodia Therapeutics kondigt onderzoekssamenwerking en licentieovereenkomst met Pfizer aan voor ontwikkeling van kleine moleculen die zich op Sec61 richten https://www.biopharmawatch.com/news/UTHR/united-therapeutics-chest-2026-meeting BiopharmaWatch en 2026-10-13T11:00:00.000Z United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting https://www.biopharmawatch.com/news/PFE/enodia-therapeutics-pfizer-sec61-complex-agreement BiopharmaWatch en 2026-10-13T11:00:00.000Z Riassunto: Enodia Therapeutics annuncia una collaborazione di ricerca e un accordo di licenza con Pfizer per sviluppare piccole molecole mirate al complesso Sec61 https://www.biopharmawatch.com/news/INMD/inmode-q3-2026-financial-results-report BiopharmaWatch en 2026-10-13T11:00:00.000Z InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M https://www.biopharmawatch.com/news/PLSM/pulsenmore-strengthens-us-commercial-leadership BiopharmaWatch en 2026-10-13T11:00:00.000Z Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer https://www.biopharmawatch.com/news/TCRT/paragon-labs-leadership-expansion-velaris-acquisition BiopharmaWatch en 2026-10-13T11:00:00.000Z Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc. https://www.biopharmawatch.com/news/NBP/hiteck-licenses-ngf-eye-drop-ht006-2-2-visara BiopharmaWatch en 2026-10-13T11:00:00.000Z Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China https://www.biopharmawatch.com/news/IRD/opus-genetics-chardan-healthcare-conference-2026 BiopharmaWatch en 2026-10-13T11:00:00.000Z Opus Genetics to Present at the Chardan Annual Healthcare Conference https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-presents-in-vivo-proof-of-concept-data BiopharmaWatch en 2026-10-13T11:00:00.000Z VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress https://www.biopharmawatch.com/news/ACON/aclarion-present-20th-annual-ld-micro-main-event BiopharmaWatch en 2026-10-13T11:00:00.000Z Aclarion to Present at the 20th Annual LD Micro Main Event https://www.biopharmawatch.com/news/MRK/merck-esmo-2026-oncology-results BiopharmaWatch en 2026-10-13T10:45:00.000Z Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026 https://www.biopharmawatch.com/news/BNTX/biontech-phase-2-3-study-bnt113-update BiopharmaWatch en 2026-10-13T10:45:00.000Z BioNTech veröffentlicht Update zur klinischen Phase-2/3-Studie des mRNA-Krebsimmuntherapiekandidaten BNT113 bei HPV16-positivem metastasiertem Kopf- und Halskrebs https://www.biopharmawatch.com/news/BNTX/biontech-update-phase-2-3-trial-bnt113-hpv16-cancer BiopharmaWatch en 2026-10-13T10:45:00.000Z BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer https://www.biopharmawatch.com/news/IMUX/immunic-inducement-grants-nasdaq-listing-rule BiopharmaWatch en 2026-10-13T10:30:00.000Z Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/JNJ/jnj-announces-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-13T10:25:00.000Z Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 https://www.biopharmawatch.com/news/GMAB/genmab-net-sales-darzalex-q3-2026 BiopharmaWatch en 2026-10-13T10:22:00.000Z Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026 https://www.biopharmawatch.com/news/JNJ/johnson-johnson-q3-2026-results-guidance BiopharmaWatch en 2026-10-13T10:20:00.000Z Johnson & Johnson reports Q3 2026 results, raises 2026 guidance https://www.biopharmawatch.com/news/IMRN/travelan-phase-2-study-results-published BiopharmaWatch en 2026-10-13T10:00:00.000Z Travelan® Phase 2 Study Results Published https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-patent-zervimesine-2045 BiopharmaWatch en 2026-10-13T10:00:00.000Z Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 https://www.biopharmawatch.com/news/BDSX/biodesix-nodify-lung-testing-chest-2026 BiopharmaWatch en 2026-10-13T10:00:00.000Z Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026 https://www.biopharmawatch.com/news/UNH/unitedhealth-group-third-quarter-2026-results BiopharmaWatch en 2026-10-13T09:55:00.000Z UnitedHealth Group Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/VCRE/vicore-pharma-chardan-healthcare-conference BiopharmaWatch en 2026-10-13T02:20:00.000Z Vicore Pharma to Participate in the Chardan Healthcare Conference https://www.biopharmawatch.com/news/TEVA/teva-rd-day-november-11-2026-new-york-city BiopharmaWatch en 2026-10-12T21:45:00.000Z Teva to Host R&D Day on Wednesday, November 11 in New York City https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-12T21:00:00.000Z Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2026-earnings-announcement BiopharmaWatch en 2026-10-12T20:49:00.000Z LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026 https://www.biopharmawatch.com/news/USNA/usana-third-quarter-2026-earnings-release BiopharmaWatch en 2026-10-12T20:30:00.000Z USANA Schedules Third Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/CSTL/tissuecypher-risk-assessment-barretts-esophagus-acg-2026 BiopharmaWatch en 2026-10-12T20:30:00.000Z ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus https://www.biopharmawatch.com/news/BMEA/biomea-fusion-phase-i-results-bmf-650 BiopharmaWatch en 2026-10-12T20:30:00.000Z Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist https://www.biopharmawatch.com/news/MDLN/medline-enhanced-trackpoint-inventory-management BiopharmaWatch en 2026-10-12T20:25:00.000Z Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care https://www.biopharmawatch.com/news/DHR/danaher-appointments-board-directors BiopharmaWatch en 2026-10-12T20:25:00.000Z Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors https://www.biopharmawatch.com/news/ORGO/organogenesis-publish-prepare-trial-results-puraply-am BiopharmaWatch en 2026-10-12T20:10:00.000Z Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-crohns-disease-remission-study BiopharmaWatch en 2026-10-12T20:05:00.000Z New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-demonstrated-sustained-clinical-endoscopic-remission-through-3-years BiopharmaWatch en 2026-10-12T20:05:00.000Z TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease https://www.biopharmawatch.com/news/HIMS/hims-hers-third-quarter-2026-results-announcement BiopharmaWatch en 2026-10-12T20:05:00.000Z Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/MYO/myomo-appoints-mary-katherine-mcclure-cco BiopharmaWatch en 2026-10-12T20:05:00.000Z Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer https://www.biopharmawatch.com/news/SVRA/savara-impala-trial-presentation-chest-2026 BiopharmaWatch en 2026-10-12T20:05:00.000Z Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-virtual-investor-event BiopharmaWatch en 2026-10-12T20:05:00.000Z Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-10-12T20:05:00.000Z Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q3-2026-financial-results BiopharmaWatch en 2026-10-12T20:05:00.000Z PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026 https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-patent-update-2026 BiopharmaWatch en 2026-10-12T20:05:00.000Z Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update https://www.biopharmawatch.com/news/ICCC/immucell-increase-product-sales-q3-2026 BiopharmaWatch en 2026-10-12T20:05:00.000Z ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results https://www.biopharmawatch.com/news/ORGO/organogenesis-third-quarter-fiscal-year-2026-results BiopharmaWatch en 2026-10-12T20:05:00.000Z Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/APMD/apnimed-presents-abstracts-chest-2026 BiopharmaWatch en 2026-10-12T20:05:00.000Z Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026 https://www.biopharmawatch.com/news/BBOT/bridgebio-oncology-therapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-20261012 BiopharmaWatch en 2026-10-12T20:05:00.000Z BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SNDX/syndax-maxpire-phase-2-trial-results-axatilimab-ipf BiopharmaWatch en 2026-10-12T20:01:00.000Z Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q3-2026-conference-call BiopharmaWatch en 2026-10-12T20:01:00.000Z Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GMED/globus-medical-q3-2026-earnings-release BiopharmaWatch en 2026-10-12T20:01:00.000Z Globus Medical Schedules Third Quarter Earnings Release and Conference Call https://www.biopharmawatch.com/news/AVBP/first-patient-dosed-arr-002-ovarian-endometrial-cancer BiopharmaWatch en 2026-10-12T20:01:00.000Z ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 https://www.biopharmawatch.com/news/CYTK/cytokinetics-acacia-hcm-hfsa-2026 BiopharmaWatch en 2026-10-12T20:00:00.000Z Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026 https://www.biopharmawatch.com/news/STE/xodus-medical-acquired-by-steris BiopharmaWatch en 2026-10-12T18:43:00.000Z Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE) https://www.biopharmawatch.com/news/REGN/pasatru-demonstrates-zero-new-ho-lesions-fop BiopharmaWatch en 2026-10-12T16:06:00.000Z Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension https://www.biopharmawatch.com/news/SNY/sanofi-voting-rights-shares-september-2026 BiopharmaWatch en 2026-10-12T16:05:00.000Z Sanofi: Information concerning the total number of voting rights and shares – September 2026 https://www.biopharmawatch.com/news/BBNX/beta-bionics-securities-fraud-class-action-ilet-fda-compliance BiopharmaWatch en 2026-10-12T15:48:00.000Z Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance https://www.biopharmawatch.com/news/PIII/p3-health-partners-appoints-chief-clinical-officer BiopharmaWatch en 2026-10-12T13:05:00.000Z P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer https://www.biopharmawatch.com/news/SBC/sbc-medical-presentation-cantor-fitzgerald-forum BiopharmaWatch en 2026-10-12T13:00:00.000Z SBC Medical to Present at Cantor Fitzgerald Hong Kong’s Inaugural Asia Longevity Forum https://www.biopharmawatch.com/news/MDT/medtronic-minimed-exchange-offer-results BiopharmaWatch en 2026-10-12T12:45:00.000Z Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer https://www.biopharmawatch.com/news/COCH/envoy-medical-fda-acclaim-cochlear-implant BiopharmaWatch en 2026-10-12T12:30:00.000Z Envoy Medical Submits Second Module of Modular Premarket Approval Application to FDA for Breakthrough Designated Acclaim(R) Cochlear Implant https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-october-2026-investor-conferences BiopharmaWatch en 2026-10-12T12:30:00.000Z Citius Pharmaceuticals to Participate in October 2026 Investor Conferences https://www.biopharmawatch.com/news/NXGL/nexgel-reverse-stock-split-effectiveness BiopharmaWatch en 2026-10-12T12:30:00.000Z NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-phase-2-data-pali-2108-acg-2026 BiopharmaWatch en 2026-10-12T12:05:00.000Z Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026 https://www.biopharmawatch.com/news/EYE/national-vision-scholarship-2026-2027 BiopharmaWatch en 2026-10-12T12:04:00.000Z National Vision Launches 2026-2027 Scholarship Program, Exploring the Balance Between Innovation and Human Connection https://www.biopharmawatch.com/news/GERN/geron-imetelstat-presentations-hematology-congresses BiopharmaWatch en 2026-10-12T12:03:00.000Z Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia https://www.biopharmawatch.com/news/OSCR/oscar-health-2026-q3-earnings-call BiopharmaWatch en 2026-10-12T12:01:00.000Z Oscar Health, Inc. 2026 Third Quarter Earnings Conference Call https://www.biopharmawatch.com/news/ARDX/ardelyx-acg-2026-ibsrela-healthcare-utilization BiopharmaWatch en 2026-10-12T12:01:00.000Z Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C https://www.biopharmawatch.com/news/MIRM/mirum-phase-3-expand-study-livmarli BiopharmaWatch en 2026-10-12T12:00:00.000Z Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-stk-002-adoa-aao-2026 BiopharmaWatch en 2026-10-12T12:00:00.000Z Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting https://www.biopharmawatch.com/news/BHC/six-month-pilot-study-cirrhosis-clinical-pathway BiopharmaWatch en 2026-10-12T12:00:00.000Z Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-phase-2a-study-od-001-vedolizumab BiopharmaWatch en 2026-10-12T12:00:00.000Z Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026 https://www.biopharmawatch.com/news/IMDX/imdx-participate-us-bancorp-btig-kidney-health-forum BiopharmaWatch en 2026-10-12T12:00:00.000Z iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings https://www.biopharmawatch.com/news/HUMA/humacyte-phase-3-v012-trial-results-asn-kidney-week-2026 BiopharmaWatch en 2026-10-12T12:00:00.000Z Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/SYK/stryker-cmr-surgical-strategic-alliance-robotic-surgery BiopharmaWatch en 2026-10-12T12:00:00.000Z Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery https://www.biopharmawatch.com/news/PHAT/phathom-new-cost-effectiveness-data-voquezna-acg-2026 BiopharmaWatch en 2026-10-12T12:00:00.000Z Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026 https://www.biopharmawatch.com/news/STE/steris-acquires-xodus-medical-surgical-products BiopharmaWatch en 2026-10-12T12:00:00.000Z STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety https://www.biopharmawatch.com/news/STRO/sutro-biopharma-participation-world-adc-conference BiopharmaWatch en 2026-10-12T12:00:00.000Z Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference https://www.biopharmawatch.com/news/CMND/clearmind-launches-automated-ev-charging-technology BiopharmaWatch en 2026-10-12T11:55:00.000Z Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-ocrelizumab-ofatumumab-analysis BiopharmaWatch en 2026-10-12T11:30:00.000Z TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis https://www.biopharmawatch.com/news/CRVO/cervomed-presents-initial-results-phase-2a-trial-neflamapimod-nonfluent-variant BiopharmaWatch en 2026-10-12T11:30:00.000Z CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026 https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-poster-presentations-fall-dermatology-2026 BiopharmaWatch en 2026-10-12T11:30:00.000Z Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026 https://www.biopharmawatch.com/news/NGEN/nervgen-first-participant-dosed-restore-phase-3-study BiopharmaWatch en 2026-10-12T11:15:00.000Z NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury https://www.biopharmawatch.com/news/RGNX/regenxbio-investor-event-surabgene-lomparvovec-wet-amd BiopharmaWatch en 2026-10-12T11:05:00.000Z REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 https://www.biopharmawatch.com/news/PODD/insulet-announces-omnipod-discover-release BiopharmaWatch en 2026-10-12T11:00:00.000Z Insulet Announces Omnipod Discover Now Available in U.S. https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-anb033-celiac-disease-results BiopharmaWatch en 2026-10-12T11:00:00.000Z First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease https://www.biopharmawatch.com/news/VANI/vivani-medical-investor-conferences-october-2026 BiopharmaWatch en 2026-10-12T11:00:00.000Z Vivani Medical Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-obexelimab-igg4-related-disease-data BiopharmaWatch en 2026-10-12T11:00:00.000Z Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-ceo-transition-growth BiopharmaWatch en 2026-10-12T11:00:00.000Z Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth https://www.biopharmawatch.com/news/IRIX/iridex-micropulse-technology-glaucoma-study BiopharmaWatch en 2026-10-12T11:00:00.000Z Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma https://www.biopharmawatch.com/news/FATE/fate-therapeutics-jamie-harrell-appointment BiopharmaWatch en 2026-10-12T11:00:00.000Z Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies https://www.biopharmawatch.com/news/BMY/bms-positive-results-phase-3-action-1-ryz101 BiopharmaWatch en 2026-10-12T10:55:00.000Z Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-synchronocity-trial-results BiopharmaWatch en 2026-10-12T10:55:00.000Z ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-phase-3-aloft-ipf-trial-admilparant BiopharmaWatch en 2026-10-12T10:50:00.000Z Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint https://www.biopharmawatch.com/news/BLCO/bausch-lomb-appoints-thomas-appio-ceo BiopharmaWatch en 2026-10-12T10:45:00.000Z Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance https://www.biopharmawatch.com/news/TFX/enrollment-completed-biomag-ll-clinical-study-tfx BiopharmaWatch en 2026-10-12T10:30:00.000Z Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261012 BiopharmaWatch en 2026-10-12T10:29:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/MNOV/medicinova-ceo-shareholder-update-phase-2-trial BiopharmaWatch en 2026-10-12T10:00:00.000Z MediciNova CEO Provides Shareholder Update https://www.biopharmawatch.com/news/RGNT/regentis-gelrinc-icrs-summit-portugal BiopharmaWatch en 2026-10-12T09:00:00.000Z Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal https://www.biopharmawatch.com/news/BMY/global-patient-week-bms-ehtiwaa-small-wins BiopharmaWatch en 2026-10-12T08:10:00.000Z On the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-12 BiopharmaWatch en 2026-10-12T07:15:20.465Z IGALMI PDUFA for Bipolar Disorders: Biotech Catalysts Oct 12, 2026 https://www.biopharmawatch.com/news/MEDS/humana-medicaid-coverage-chemofx-assay-gynecologic-cancers BiopharmaWatch en 2026-10-12T06:00:00.000Z DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers https://www.biopharmawatch.com/news/MIRM/mirum-investor-call-phase-3-expand-study-livmarli BiopharmaWatch en 2026-10-11T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-anb033-phase-1b-trial-data BiopharmaWatch en 2026-10-11T20:00:00.000Z First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 https://www.biopharmawatch.com/news/BBIO/acoramidis-improves-outcomes-vs-tafamidis-attr-cm BiopharmaWatch en 2026-10-11T18:30:00.000Z Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records https://www.biopharmawatch.com/news/FRNM/freenome-new-validation-data-crc-screening-test-acg-2026 BiopharmaWatch en 2026-10-11T17:00:00.000Z Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 https://www.biopharmawatch.com/news/BBIO/encaleret-phase-3-calibrate-trial-results BiopharmaWatch en 2026-10-11T15:42:00.000Z Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1